Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | BTK | Q06187 | 3/20 | 0.39 |
| ▸ | LPL | P06858 | 10/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24773231 | 0.88 | LPL (0.42) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL746647 | 0.83 | JAK2 (0.42) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL20540203 | 0.83 | LPL (0.39) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL30550009 | 0.83 | JAK2 (0.42) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL14878282 | 0.81 | JAK2 (0.41) | JAK2BTKLPLLIPGP2RX7 | |
| SCHEMBL6686927 | 0.80 | LPL (0.47) | JAK2BTKLPLLIPGP2RX7 | |
| SCHEMBL8258588 | 0.80 | JAK2 (0.41) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL21673131 | 0.80 | LPL (0.37) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL1494643 | 0.80 | LPL (0.37) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL30772451 | 0.80 | LPL (0.37) | JAK2BTKLPLLIPGEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-114615981-B | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230322675-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230077225-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
| US-11453683-B1 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2022-09-27 | — | — | US | disclosed |
| EP-4021444-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20190077792-A1 | Octahydrocyclopenta[c]pyrrole Allosteric Inhibitors of SHP2 | Krouzon Pharmaceuticals, Inc. | 2019-03-14 | — | — | US | disclosed |
| US-20190077792-A1 | Octahydrocyclopenta[c]pyrrole Allosteric Inhibitors of SHP2 | Krouzon Pharmaceuticals, Inc. | 2019-03-14 | — | — | US | disclosed |
| WO-2019051469-A1 | OCTAHYDROCYCLOPENTA[C]PYRROLE ALLOSTERIC INHIBITORS OF SHP2 | Krouzon Pharmaceuticals, Inc. (US) | 2019-03-14 | — | — | WO | disclosed |
| WO-2019051469-A1 | OCTAHYDROCYCLOPENTA[C]PYRROLE ALLOSTERIC INHIBITORS OF SHP2 | Krouzon Pharmaceuticals, Inc. (US) | 2019-03-14 | — | — | WO | disclosed |
| EP-3208263-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VentiRx Pharmaceuticals, Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9718796-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| EP-2663550-B1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20140066432-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | VENTIRX PHARMACEUTICALS, INC. | 2014-03-06 | — | — | US | disclosed |
| EP-2663550-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VentiRx Pharmaceuticals, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| WO-2012097173-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322675-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR2, LPAR1, LPAR6 | JAK2 1769/4885BTK 1949/4885LPL 11/4885 |
| US-20190077792-A1 | Octahydrocyclopenta[c]pyrrole Allosteric Inhibitors of SHP2 | PTPN1, PTPN2, PTPN7 | JAK2 50/4885BTK 69/4885LPL 2229/4885 |
| US-20230279025-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | JAK2 1113/4885BTK 2099/4885LPL 4166/4885 |
| US-20230077225-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | JAK2 1126/4885BTK 2179/4885LPL 4181/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | JAK2 435/4885BTK 1170/4885LPL 3982/4885 |
| US-20140066432-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | TLR8, TLR9, TLR1 | JAK2 323/4885BTK 128/4885LPL 1207/4885 |
| US-11964989-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | JAK2 401/4885BTK 2352/4885LPL 3923/4885 |
| US-11453683-B1 | KRas G12D inhibitors | KRAS, NRAS, HRAS | JAK2 414/4885BTK 2337/4885LPL 3911/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | JAK2 1126/4885BTK 2179/4885LPL 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.